Bavarian Nordic AS (LTS:0DPB) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0DPB Bavarian Nordic AS LTS:0DPB
77 GF Score
Price kr185.70
GF Value kr162.71
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Bavarian Nordic AS FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0DPB
77GF Score
Bavarian Nordic AS LTS:0DPB
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bavarian Nordic AS (LTS:0DPB) Overvalued in 2026?

Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued. The current stock price of kr185.70 is trading 14.1% above its estimated GF Value™ of kr162.71. GuruFocus considers Bavarian Nordic AS to be Modestly Overvalued.

Key valuation signals for LTS:0DPB:

  • FFO:
  • GF Value™: kr162.71 vs. price of kr185.70 (14.1% above fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the LTS:0DPB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bavarian Nordic AS Business Description

Address Philip Heymans Alle 3, Hellerup, DNK, 2900
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
77GF Score

Get the complete analysis for LTS:0DPB

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr185.70
Price
kr162.71
GF Value